^
Association details:
Biomarker:NUP98-KDM5A fusion
Cancer:Acute Myelogenous Leukemia
Drug Class:T-lymphocyte cell therapy
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

1531: Developing Immunocompetent Models to Evaluate B7-H3-CAR T Cells for Acute Myeloid Leukemia

Published date:
05/02/2023
Excerpt:
To test in vivo antitumor activity, mice were engrafted with 1e6 NUP98:KDM5A cells. A single of infusion of 3e6 mB7-H3-CAR T cells demonstrated significant anti-AML activity (p<0.001) when compared to control-CAR T cells, resulting in a survival advantage (p<0.01, N=5/group)....We demonstrate that mB7-H3-CAR T cells have potent anti-AML activity in vitro and in vivo.